PARD has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
PARD has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Poniard Pharmaceuticals's cost of goods sold for the three months ended in Sep. 2011 was $0.00 Mil. Its cost of goods sold for the trailing twelve months (TTM) ended in Sep. 2011 was $0.00 Mil.
Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Poniard Pharmaceuticals's Gross Margin % for the three months ended in Sep. 2011 was %.
Cost of Goods Sold is also directly linked to Inventory Turnover.
The historical data trend for Poniard Pharmaceuticals's Cost of Goods Sold can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Poniard Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec01 | Dec02 | Dec03 | Dec04 | Dec05 | Dec06 | Dec07 | Dec08 | Dec09 | Dec10 | |||||||||||
Cost of Goods Sold | Get a 7-Day Free Trial | - | - | - | - | - |
Poniard Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Dec06 | Mar07 | Jun07 | Sep07 | Dec07 | Mar08 | Jun08 | Sep08 | Dec08 | Mar09 | Jun09 | Sep09 | Dec09 | Mar10 | Jun10 | Sep10 | Dec10 | Mar11 | Jun11 | Sep11 | |
Cost of Goods Sold | Get a 7-Day Free Trial | - | - | - | - | - |
Cost of Goods Sold is the aggregate cost of goods produced and sold, and services rendered during the reporting period. It excludes Total Operating Expense, such as Depreciation, Depletion and Amortization and Selling, General, & Admin. Expense.
Cost of Goods Sold for the trailing twelve months (TTM) ended in Sep. 2011 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Poniard Pharmaceuticals (OTCPK:PARD) Cost of Goods Sold Explanation
Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.
Poniard Pharmaceuticals's Gross Margin % for the three months ended in Sep. 2011 is calculated as:
Gross Margin % | = | (Revenue | - | Cost of Goods Sold) | / | Revenue |
= | (0 | - | 0) | / | 0 | |
= | % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.
Cost of Goods Sold is also directly linked to another concept called Inventory Turnover:
Poniard Pharmaceuticals's Inventory Turnover for the three months ended in Sep. 2011 is calculated as:
Inventory Turnover | = | Cost of Goods Sold | / | Average Total Inventories |
= | 0 | / | 0 | |
= | N/A |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Inventory Turnover measures how fast the company turns over its inventory within a year. A higher inventory turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.
Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate inventory turnover. An average inventory is a better indication.
Thank you for viewing the detailed overview of Poniard Pharmaceuticals's Cost of Goods Sold provided by GuruFocus.com. Please click on the following links to see related term pages.
Michael S Perry | officer: President & CMO | C/O BIOTRANSPLANT INC, 196 BOSTON AVE SUITE 2800, MEDFORD MA 02155 |
Ron Martell | director, officer: Chief Executive Officer | PONIARD PHARMACEUTICALS, INC., 750 BATTERY STREET, SUITE 330, SAN FRANCISCO CA 94111 |
Gary A Lyons | director | 12790 EL CAMINO REAL, C/O NEUROCRINE BIOSCIENCES, SAN DIEGO CA 92130 |
David R Stevens | director | 300 ELLIOTT AVENUE WEST, SUITE 500, SEATTLE WA 98119-4114 |
Gerald Phd Mcmahon | director | 300 ELLIOTT AVENUE WEST, SUITE 500, SEATTLE WA 98119-4114 |
Carl Goldfischer | director | 161 WEST 61ST STREET, NEW YORK NY 10022 |
Fred B Craves | director | 750 BATTERY ST, STE 600, SAN FRANCISCO CA 94111 |
Simon Nicholas J Iii | director, 10 percent owner | THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH FLOOR, BOSTON MA 02116 |
Gregory L Weaver | officer: Chief Financial Officer | 185 BERRY STREET, SUITE 6504, SAN FRANCISCO CA 94107 |
Kurt Wheeler | 10 percent owner | 801 GATEWAY BLVD, STE 410, SAN FRANCISCO CA 94080 |
Mpm Asset Management Investors 2005 Bviii Llc | 10 percent owner | C/O MPM ASSET MANAGEMENT, 111 HUNTINGTON AVENUE 31ST FLOOR, BOSTON MA 02199 |
Nicholas Galakatos | 10 percent owner | THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH FLOOR, BOSTON MA 02116 |
Dennis Henner | 10 percent owner | THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH FLOOR, BOSTON MA 02116 |
Michael Steinmetz | 10 percent owner | THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH FLOOR, BOSTON MA 02116 |
Luke Evnin | 10 percent owner | THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH STREET, BOSTON MA 02116 |
From GuruFocus
By GuruFocus Research GuruFocus Editor • 08-22-2009
By gurufocus 10qk • 11-06-2009
By gurufocus • 05-12-2009
By gurufocus 10qk • 11-09-2010
By gurufocus • 04-06-2009
By gurufocus • 08-07-2009
By gurufocus 10qk • 05-10-2010
By gurufocus 10qk • 08-09-2010
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.